Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator,
Vor Bio's partner tested a medicine for a muscle disease in China. The medicine helped over 95% of patients get better over one year.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.